Shares of Rocket Lab Corporation (NASDAQ:RKLB) edged higher in premarket trading on Wednesday, August 12, 2026, as investors weighed a record order backlog and robust quarterly results against ongoing uncertainty surrounding the debut of the company's Neutron rocket. The stock gained 1.2% to $80.99 by 05:30 EDT, following a session on Tuesday that saw shares recover from an early 8.8% decline to close nearly flat at $80.01.
The company reported second-quarter revenue of $234.1 million, a 62% increase year-over-year, surpassing its own guidance range of $225 million to $240 million. Product sales surged to $181.3 million, representing 77.5% of total revenue, while service revenue contributed $52.7 million. The GAAP net loss narrowed by 26% to $49.3 million, or $0.08 per share, compared to a loss of $0.13 per share in the same quarter last year.
Investors have focused on the company's record backlog, which climbed to $2.36 billion, up 137% from a year earlier and 7.3% sequentially. The backlog now represents roughly 2.5 times the annualized second-quarter revenue, providing a strong visibility cushion against potential launch schedule disruptions. However, execution risk remains, particularly as the company navigates the development of its medium-lift Neutron rocket.
For the third quarter, Rocket Lab guided revenue in the range of $250 million to $265 million, with a midpoint of $257.5 million—about 10% higher than the second quarter and approximately 8% above the prior analyst consensus of $238.5 million. This optimistic outlook is underpinned by more than $1 billion in new contracts awarded during the third quarter, including a $266 million contract with the U.S. Space Force for up to 18 suborbital launches, the company's largest launch contract to date.
Despite the strong financial performance, concerns persist over the timing of Neutron's inaugural flight. The company plans to roll the rocket to the launch pad during the fourth quarter, but CEO Peter Beck acknowledged that the 'window for an end-of-year launch is narrowing.' This has led to a cautious stance among some analysts, with price targets ranging from $60 (Wells Fargo) to $135 (KeyBanc). The average analyst target stands at $110.93, implying roughly 37% upside from current levels. Of the 17 analysts covering the stock, 13 rate it a Buy, 4 a Hold, and none a Sell.
Rocket Lab's valuation remains elevated, with a market capitalization of approximately $47.9 billion—about 20 times its backlog. This metric does not represent a price-to-sales ratio, as backlog is recognized gradually over time. The company's beta of 2.60 and thin premarket trading volumes could amplify price volatility, especially as investors monitor Neutron's progress and the conversion of backlog into revenue.
Looking ahead, the key focus for investors will be whether Rocket Lab can continue to execute on its backlog while managing development costs. If third-quarter results align with the midpoint of guidance, revenue growth will remain strong. However, the arrival of Neutron hardware at the launch pad will be a more significant milestone, as it would de-risk the timeline and potentially unlock further upside. Each step toward that goal will be closely watched by the market.
